Ascendis presents first Infant Data from once-weekly TransCon CNP trial
Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment. TransCon CNP increased linear growth in a sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.